Dive Brief:

简报：

Pfizer

辉瑞

will pay Chinese drugmaker YaoPharma $150 million

将向中国制药商姚药业支付 1.5 亿美元

for rights to an experimental obesity pill as the company works to catch up in a market dominated by Eli Lilly and Novo Nordisk.

为了获得一种实验性减肥药的权益，该公司正在努力追赶礼来和诺和诺德主导的市场。

The deal, announced Tuesday, includes as much as $1.94 billion in further payments for reaching certain developmental, regulatory and commercial milestones. YaoPharma, a unit of Shanghai-based Fosun Pharma, will also be eligible for royalties if the drug reaches the market.

周二宣布的这笔交易包括高达 19.4 亿美元的额外付款，用于达成某些发展、监管和商业里程碑。如果该药物上市，复星医药旗下重庆药友制药还将有资格获得特许权使用费。

The GLP-1 agonist, dubbed YP05002, is currently in Phase 1 testing and YaoPharma will continue that research, Pfizer said. The New York-based drugmaker will be responsible for further development and says it plans to conduct combination studies with one of its own pipeline drugs, PF-07976016, a different type of obesity treatment currently in Phase 2..

辉瑞表示，这款名为YP05002的GLP-1激动剂目前正处于一期测试阶段，药明康德将继续进行该研究。这家总部位于纽约的制药商将负责进一步的开发工作，并计划将其与自家另一款处于二期临床阶段、不同类型的肥胖症治疗药物PF-07976016进行联合研究。

Dive Insight:

潜水洞察：

Pfizer is struggling to regain traction after the end of the coronavirus pandemic eviscerated sales of its successful COVID-19 products. Pfizer’s stock is trading at less than half of the highs reached in late 2021 when its Comirnaty vaccine

辉瑞在冠状病毒大流行结束后，其成功的COVID-19产品销售额受到重创，目前正努力重新获得市场动力。辉瑞的股票交易价格不到2021年底Comirnaty疫苗推出时高点的一半。

was raking in billions of dollars

赚取了数十亿美元

.

。

By late 2023, Pfizer’s results were

截至2023年底，辉瑞的结果是

falling short of Wall Street expectations

未能达到华尔街的预期

. The company began

公司开始了

cutting costs

削减成本

and looking to other areas for growth, including a $43 billion takeover of Seagen that led to a new business unit

并且寻求在其他领域实现增长，包括以430亿美元收购Seagen，从而创建了一个新的业务部门。

dedicated to cancer research

致力于癌症研究

.

。

The surging obesity market was an obvious target for Pfizer. But the company’

肥胖症市场的快速增长显然是辉瑞的目标。但是这家公司

initial attempts to gain entry fell flat

初步的尝试获取准入资格失败了。

as two experimental oral medicines weren’t safe enough to warrant further development. Pfizer has more recently turned to dealmaking for help, winning a bidding war with Novo Nordisk to

由于两种实验性口服药物不够安全，不值得进一步开发。辉瑞最近转向通过交易寻求帮助，在与诺和诺德的竞标战中胜出。

take over obesity drug developer Metsera for $10 billion

以100亿美元收购肥胖症药物开发商Metsera

.

。

YaoPharma’s medicine offers Pfizer another shot at an oral version of the popular injectable GLP-1 drugs. According to Leerink Partners analyst David Risinger, YP05002 is different than one of Pfizer’s failed medicines, danuglipron, with a chemical scaffold similar to a

姚制药的药物为辉瑞提供了另一种口服版本的流行注射型GLP-1药物的机会。据Leerink Partners分析师大卫·莱辛格称，YP05002与辉瑞失败的药物之一丹那利普隆不同，其化学骨架与某种药物相似。

treatment called orforglipron

名为orforglipron的治疗方案

being advanced by Lilly.

由礼来公司提出。

Still, Lilly and Novo are far ahead in the race to advance oral GLP-1 medicines. Novo is

尽管如此，礼来和诺和在推进口服GLP-1药物的竞争中仍遥遥领先。诺和

hoping for Food and Drug Administration approval

希望获得食品和药物管理局的批准

of the pill version of its Wegovy medication this month. And Lilly is looking for an

本月，其Wegovy药物的药丸版本。而礼来公司正在寻找一种方法。

FDA decision

FDA决定

on orforglipron in the first half of next year after winning one of the agency’s new

在明年上半年，赢得机构新成立的其中一个部门后，开始负责orforglipron。

review vouchers

审核凭证

for the drug.

对于这种药物。

Pfizer’s decision to tap into China is

辉瑞决定进军中国是

part of a broader movement among U.S. companies

美国公司更广泛运动的一部分

to license drugs from a market with more regulatory flexibility and lower costs. Earlier this year, Pfizer inked a deal with the

从监管更灵活、成本更低的市场获得药品许可。今年早些时候，辉瑞与

Chinese biotechnology company 3SBio

中国生物技术公司三生制药

that included an upfront payment of $1.25 billion for a dual-targeting cancer treatment.

其中包括为一种双靶向癌症治疗支付的12.5亿美元预付款。